Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Designates 5 Products including Dornase as Orphan Drugs
July 4, 2011
- Ethical Drug Market in Japan Grew 1.6% to ¥9,035,806 Mil. in FY2010: IMS Japan
July 4, 2011
- METI Advisory Committee Proposes Exclusion of OTC-like Drugs from Insurance Coverage
July 4, 2011
- Sprycel Approved as 1st-line Treatment for CML: Bristol-Myers, Otsuka
July 4, 2011
- Wakamoto Licenses Ophthalmic Surgical Adjuvant from Kyushu Univ. Bioventure
July 4, 2011
- PMDA to Give Priority to Regenerative Medicine, Cancer in Regulatory Strategy Consultation
July 4, 2011
- Number of Deaths Reached Post-war High in 2010: Korosho
July 4, 2011
- Astellas Transfers Luvox to Abbott Japan
July 4, 2011
- Korosho Asks Takeda to Revise Package Insert for Actos
July 4, 2011
- With Right Infrastructure, “Bright Future”for Multinational Trials: Mr Morimoto of CMIC
July 4, 2011
- Sosei Group to Collaborate with Gifu Pharm. Univ.
July 4, 2011
- Korosho Instructs Revision of Package Inserts for Pioglitazone
July 4, 2011
- Korosho to Select 5 Hub Med. Institutions for Early-stage Clinical Studies
July 4, 2011
- Tsuruha HD: Dispensing Fees Up 10.2% in FY2010
July 4, 2011
- EMA to Issue Conclusion on Bladder Cancer Risk from Actos in July
July 4, 2011
- AnGes MG Obtains Patent on HVJ-E for Cancer
July 4, 2011
- R&I Upgrades Kaken's Rating from “Stable”to “Positive”
July 4, 2011
- Takeda Applies for SGN-35 in Europe
July 4, 2011
- Current Users to Be Permitted to Rely on Telemarketing to Buy Reclassified Class 2 OTC Drugs
July 4, 2011
- R&I Keeps AA- Rating for Eisai
July 4, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…